What is MediPines?
MediPines is at the forefront of developing advanced, non-invasive cardiorespiratory assessment solutions. Their flagship product, the AGM100, is engineered to deliver rapid and accurate detection of respiratory impairment, a critical capability for emergency care settings. This technology empowers clinicians with actionable data in under two minutes, thereby enhancing patient safety and optimizing healthcare workflows. The company's focus on improving the diagnosis and management of conditions such as COPD, pneumonia, and acute asthma positions it as a key player in the medical device industry.
How much funding has MediPines raised?
MediPines has raised a total of $2.6M across 2 funding rounds:
Private Equity
$563K
Private Equity
$2M
Private Equity (2013): $563K, investors not publicly disclosed
Private Equity (2015): $2M, investors not publicly disclosed
What's next for MediPines?
The recent major strategic investment suggests MediPines is poised for significant expansion and further development of its assessment technology. This enterprise-level funding will likely fuel advancements in product capabilities, market penetration, and strategic partnerships within the healthcare ecosystem. As MediPines continues to scale its operations, the company is expected to solidify its position as a leader in non-invasive diagnostic tools, driving innovation in respiratory care and improving patient outcomes globally.
See full MediPines company page
